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Caveolae are flask-shaped invaginations of the plasma membrane. Caveolins are the major 
protein component building these caveolae. Caveolins are involved in cell signaling and play a 
role multiple subcellular processes, such as endocytosis. Of the three types of caveolins 
(numbered 1, 2, and 3), most research has been performed on caveolin-1. For example, in the 
field of cancer, it has been found that caveolin-1 has the ability to either suppress or encourage 
growth of cancer cells (depending on the type of cancer). Interestingly, it has been reported that 
the level of both caveolin-1 and -2 increases in drug resistant cancer cell lines. However, it is 
unknown if such increases are coincidental or actually play an important role in the development 
of drug resistance. The major goal of this study is to better understand the role of caveolins-1 
and -2 in the growth and drug resistance of A549 lung adenocarcinoma. For this purpose, the 
levels of caveolin-1 and -2 were dramatically reduced (knocked down) using small interfering 
RNA (siRNA) stably expressed in A549 cells. The efficient reduction of caveolin-1 and -2 levels 
by siRNA has been confirmed by Western Blot. By using colorimetric assay and cell count, we 
are currently determining the possible differences in growth of A549 cell populations expressing 
control siRNA and caveolin-1 or -2 siRNA in the absence or presence of different concentrations 
of two anticancer drugs, i.e., taxol and etoposide. We hypothesize that in the absence of drugs, 
cells with a knockdown of caveolin-1 or -2 will grow equally as fast as or faster than control 
cells. Conversely, we expect that knockdown of caveolins will increase sensitivity of A549 to 
anti-cancer drugs and limit the possibility of developing drug resistance. Such results would be a 
first direct evidence that caveolin-1 and/or -2 are involved in acquiring drug resistance. If the 
latter is true, targeting caveolins in lung adenocarcinomas and other cancers could limit or even 
prevent the development of drug resistance and thus increase the efficacy of anti-cancer drugs.   
   
